Mersana Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Mersana Therapeutics generated cash of -$168,882,000, which is less than the previous year. Cash used in financing activities reached the amount of $94,675,000 last year. Net change in cash is therefore $45,676,000.
Cash Flow
| 2015 | -9.63M | -783K | 9.96M |
|---|---|---|---|
| 2016 | 31.58M | -1.08M | 58.25M |
| 2017 | -42.67M | -99.62M | 68.59M |
| 2018 | -55.21M | 87.19M | 1.06M |
| 2019 | -67.74M | -27.29M | 97.70M |
| 2020 | -74.69M | 37.02M | 230.41M |
| 2021 | -139.98M | -648K | 63.64M |
| 2022 | -49.36M | -152.71M | 153.01M |
| 2023 | -168.88M | 119.88M | 94.67M |
MRSN Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 129.36M | 178.42M | 255.41M | 62.67M | 60.00M | 26.96M | 100.29M | 11.53M | 11.99M |
Operating activities | |||||||||
Net income | -171.67M | -204.21M | -170.06M | -88.04M | -28.20M | -64.25M | -38.70M | -13.7M | -16.42M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 1.51M | 927K | 855K | 1.01M | 1.24M | 1.25M | 928K | 655K | 297K |
Stock-based compensation expense | 21.13M | 21.52M | 18.40M | 7.17M | 4.87M | 3.88M | 1.42M | 668K | 349K |
| Deferred income tax benefit | 21.13M | 21.52M | 18.40M | 7.17M | 4.87M | 3.88M | 1.42M | 668K | 349K |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | 30M | -30M | 0 | 0 | 459K | 325K | 267K | -411K | 1.19M |
Inventories | 0 | 0 | 0 | 0 | -1.50M | 2.60M | 2.42M | 1.42M | 304K |
Accounts payable | -6.08M | 947K | 483K | 942K | -3.11M | 7.37M | 1.33M | -325K | 926K |
Cash generated by operating activities | -168.88M | -49.36M | -139.98M | -74.69M | -67.74M | -55.21M | -42.67M | 31.58M | -9.63M |
Investing activities | |||||||||
Purchases Of Investments | -155.91M | -247.51M | 0 | 0 | -53.68M | 0 | -145.70M | 0 | -164K |
Investments In Property Plant And Equipment | -2.16M | -2.19M | -648K | -473K | -605K | -1.37M | -1.14M | -1.08M | -619K |
Acquisitions Net | 0 | 150.51M | 0 | 0 | 26.68M | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 119.88M | -152.71M | -648K | 37.02M | -27.29M | 87.19M | -99.62M | -1.08M | -783K |
Financing activities | |||||||||
Common Stock Issued | 93.53M | 150.89M | 43.08M | 227.02M | 92.16M | 0 | 68.14M | 0 | 9.96M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 640K | 561K | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -262K | -272K | -5.70M | -313K | 4.87M | 0 | 0 | 0 | 0 |
Cash used in financing activities | 94.67M | 153.01M | 63.64M | 230.41M | 97.70M | 1.06M | 68.59M | 58.25M | 9.96M |
Net Change In Cash | 45.67M | -49.06M | -76.99M | 192.74M | 2.66M | 33.04M | -73.70M | 88.76M | -459K |
Cash at end of period | 175.03M | 129.36M | 178.42M | 255.41M | 62.67M | 60.00M | 26.59M | 100.29M | 11.53M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |